MOUNTAIN VIEW, Calif., Oct. 14, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) announced today that it will introduce its new family of patented Adjustable & Intuitive Extended Reach (A&I XR) laser probes at the annual meeting of the American Academy of Ophthalmology to be held October 18 - 21 at McCormick Place in Chicago. The A&I XR laser probes are used for laser photocoagulation during vitreoretinal procedures. These new devices offer unprecedented uniformity and consistency of treatment using both straight and angled configurations that allow the surgeon to comfortably reach all parts of the anatomy.
Vitreoretinal procedures include the management of a variety of conditions that affect the vitreous and retina that lie on the back part of the eye, such as diabetic retinopathy, macular degeneration, retinal detachments or tears and macular holes.
Dr. Sam Mansour, Medical Director of Virginia Retina Center in Warrenton, VA, and Clinical Professor of Ophthalmology at The George Washington University in Washington, DC, commented, "Using the A&I XR probe, I was able to reach the full periphery of the eye. Its narrow cone angle allowed me to treat with lower power and further from the retina than with other laser probes. This results in enhanced physician visualization and improves patient safety."
The A&I XR laser probes are available in 20-, 23-, and 25-gauge models with the option of finger or thumb actuators to smoothly guide the extension and retraction of the laser fiber.
"Our new devices further enhance our robust line of premium laser probes, and amplifies our efforts to quickly design and launch consumable products to further grow our procedural based recurring revenues," said Will Moore, IRIDEX President and CEO.
About IRIDEX
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the time of release, availability, effectiveness and safety of Company products, and the Company's future financial performance. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2013, which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
SOURCE IRIDEX Corporation
IRIDEX Contact: Jim Mackaness, CFO & COO, 650-940-4700, Investor Relations Contact: Matt Clawson, Pure Communications, 949-370-8500, matt@purecommunicationsinc.com
